Adalimumab as treatment for neurosarcoidosis: A case series
Sarcoidosis is a disease characterized by non-caseating granulomas that can involve the central nervous system as neurosarcoidosis. This challenging disease is currently managed with high dose steroids, and sometimes the addition of infliximab. Other TNA-alpha inhibitors have not been studied as rigorously. We discovered ten neurosarcoidosis patients who were on an alternative TNA-alpha inhibitor, adalimumab. Eight patients had a positive response clinically and radiographically to adalimumab.
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Jeffrey Shen, Megumi Sugita, Andrea Linares-Lopez, Suma Shah, Christopher Eckstein, Elijah Lackey Tags: Clinical short communication Source Type: research